Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF). Momelotinib treatment-emergent peripheral neuropathy (TE-PN) was documented in 44 (44%) of 100 MF patients treated at our institution; median time of TE-PN onset was 32 weeks and duration 11 months. Improvement after drug dose reduction or discontinuation was documented in only two patients. TE-PN was significantly associated with treatment response (P = 0·02) and longer survival (P = 0·048) but significance was lost during multivariate analysis that included treatment duration. TE-PN did not correlate with initial or maximum momelotinib dose or previous treatment with JAK inhibitor or thalidomide.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalBritish journal of haematology
Volume169
Issue number1
DOIs
StatePublished - Apr 1 2015

Keywords

  • Momelotinib
  • Myelofibrosis
  • Myeloproliferative
  • Neuropathy

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis'. Together they form a unique fingerprint.

  • Cite this